Literature DB >> 17032570

Cholesterol lowering to prevent stroke: who, when, and how?

Richard A Bernstein1.   

Abstract

The epidemiologic link between increased low-density-lipoprotein (LDL) cholesterol and ischemic stroke is controversial. However, recent trials make it clear that LDL reduction by statin agents in high-risk patients reduces the risk of ischemic stroke. The risk of first stroke is reduced within 1 to 2 years of statin therapy in patients at high risk for ischemic vascular disease. Patients with any history of cerebrovascular disease who are treated with statins have a reduced risk of coronary ischemic events and of all major vascular ischemic events, independent of any history of coexisting coronary artery disease. In particular, patients with recent transient ischemic attack or ischemic stroke show significantly reduced risks of both recurrent stroke and coronary events when they are treated with high-dose statin therapy. Most patients with ischemic cerebrovascular disease should be placed on statin drugs. However, most stroke patients are not currently treated to recommended levels with these agents, providing ample room for improvement in physician performance.

Entities:  

Year:  2006        PMID: 17032570     DOI: 10.1007/s11940-006-0039-1

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.972


  29 in total

Review 1.  The value of lowering cholesterol after myocardial infarction.

Authors:  J E Rossouw; B Lewis; B M Rifkind
Journal:  N Engl J Med       Date:  1990-10-18       Impact factor: 91.245

2.  Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy.

Authors:  Christopher P Cannon; Benjamin A Steinberg; Sabina A Murphy; Jessica L Mega; Eugene Braunwald
Journal:  J Am Coll Cardiol       Date:  2006-07-12       Impact factor: 24.094

3.  Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial.

Authors:  H Iso; D R Jacobs; D Wentworth; J D Neaton; J D Cohen
Journal:  N Engl J Med       Date:  1989-04-06       Impact factor: 91.245

Review 4.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.

Authors:  Scott M Grundy; James I Cleeman; C Noel Bairey Merz; H Bryan Brewer; Luther T Clark; Donald B Hunninghake; Richard C Pasternak; Sidney C Smith; Neil J Stone
Journal:  Circulation       Date:  2004-07-13       Impact factor: 29.690

5.  Ten-year risk of first recurrent stroke and disability after first-ever stroke in the Perth Community Stroke Study.

Authors:  Kate Hardie; Graeme J Hankey; Konrad Jamrozik; Robyn J Broadhurst; Craig Anderson
Journal:  Stroke       Date:  2004-02-05       Impact factor: 7.914

Review 6.  Effects of statins on stroke prevention in patients with and without coronary heart disease: a meta-analysis of randomized controlled trials.

Authors:  Matthias Briel; Marco Studer; Tracy R Glass; Heiner C Bucher
Journal:  Am J Med       Date:  2004-10-15       Impact factor: 4.965

7.  Lipids and risk of coronary heart disease. The Framingham Study.

Authors:  W P Castelli; K Anderson; P W Wilson; D Levy
Journal:  Ann Epidemiol       Date:  1992 Jan-Mar       Impact factor: 3.797

8.  Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective studies collaboration.

Authors: 
Journal:  Lancet       Date:  1995 Dec 23-30       Impact factor: 79.321

9.  Serum total cholesterol and mortality. Confounding factors and risk modification in Japanese-American men.

Authors:  C Iribarren; D M Reed; C M Burchfiel; J H Dwyer
Journal:  JAMA       Date:  1995-06-28       Impact factor: 56.272

10.  Effects of acute treatment with pravastatin on cerebral vasospasm, autoregulation, and delayed ischemic deficits after aneurysmal subarachnoid hemorrhage: a phase II randomized placebo-controlled trial.

Authors:  Ming-Yuan Tseng; Marek Czosnyka; Hugh Richards; John D Pickard; Peter J Kirkpatrick
Journal:  Stroke       Date:  2005-08       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.